Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT05848310
Recruiting Observational

Preoperative Serum FGF19 in the Prognosis of Biliary Atresia

NCT05848310 · tracked via the Priya Life Science China tracker
Sponsor
Children's Hospital of Fudan University
Phase
Observational
Started
2023-10-15
Last updated
2026-03-27

Condition(s) studied

Biliary AtresiaPrognosis

Study summary

To investigate the role of preoperative serum FGF19 level in the prognosis of biliary atresia.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Samples diagnosed as biliary atresia in Children's Hospital of Fudan University * Samples with one-year follow-up records after surgery * Samples with a record of serum total bilirubin levels three months after surgery * Samples with preoperative serum left（volume \> 500ul) Exclusion Criteria: * None

Primary outcome measure(s)

  • Serum total bilirubin level (umol/l) — Three months after surgery
    The difference of serum total bilirubin level will be measured with ELISA( Enzyme Linked ImmunoSorbent Assay) three months after surgery
  • Native liver survival (%) — One year after surgery
    The difference of native liver survival will be measured according to the follow-up statue one year after surgery

Trial sites (1)

FacilityCityRegionStatus
Children's Hospital of Fudan University Shanghai Shanghai Municipality Recruiting

More Children's Hospital of Fudan University trials in China

Clinical Implementation of the Group Standard for Enteral Feeding Care in Critically Ill Children Starting soon
PK/PD of Ceftazidime Avitbatan Sodium in Children With Severe Infection Recruiting
YTS109 in Pediatric Relapsed/Refractory Autoimmune Diseases Starting soon
Development of an Early Warning Model for Intensive Care Unit-Acquired Weakness in Mechanically Ventilated Children Enrolling by invitation
Interactive Massage Intervention in Toddlers With Autism Spectrum Disorder Recruiting

Other trials for the same condition

Effect of Bone Augmentation Simultaneous to Implant Removal on the Prognosis of Reimplantation at the Same Site Recruiting
Cardiac Magnetic Resonance-Clinical Prediction Model-Dilated Cardiomyopathy Recruiting
An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary Atresia Active, not recruiting
Molecular Subtype-Guided Postoperative Radiotherapy for Phyllodes Tumor of the Breast Starting soon
Nutritional Intervention for Biliary Atresia Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05848310 on ClinicalTrials.gov ↗ ← All trials in China